Clinical Trials Browser

Interventional × Liver Neoplasms × cabozantinib × Clear all

NCT03299946 2024-09-03

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT05039736 2023-05-12

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01908426 2021-05-06

CELESTIAL

Phase 3 Completed

707 enrolled 20 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms